Understanding the Market | CT ENTERPRISE fell over 7%, expecting third-quarter net profit to drop to approximately USD 6.5 million

Zhitong
2025.10.22 06:40
portai
I'm PortAI, I can summarize articles.

CT ENTERPRISE fell over 7%, as of the time of publication, down 7.07% to HKD 7.62, with a trading volume of HKD 5.4218 million. In terms of news, on the evening of October 21, CT ENTERPRISE announced that it expects to achieve an unaudited consolidated profit attributable to shareholders of approximately USD 23.5 million for the nine months ending September 30, 2025, compared to USD 4.3 million in the same period last year, a year-on-year increase of 4.47 times. The growth in profit is mainly due to a significant increase in revenue, reflecting the successful implementation of key strategies for developing major customer sales. However, due to the slowdown in China's livestock industry, the demand for the company's veterinary pharmaceutical products is also expected to decrease starting from the third quarter of 2025. The group's unaudited quarterly consolidated profit attributable to shareholders for the three months ending September 30, 2025, is expected to drop to approximately USD 6.5 million, compared to USD 9.3 million for the three months ending June 30, 2025

According to Zhitong Finance APP, CT ENTERPRISE (03839) fell over 7%, down 7.07% to HKD 7.62 as of the time of writing, with a trading volume of HKD 5.4218 million.

In terms of news, on the evening of October 21, CT ENTERPRISE announced that it expects to achieve an unaudited consolidated profit attributable to shareholders of approximately USD 23.5 million for the nine months ending September 30, 2025, compared to USD 4.3 million in the same period last year, representing a year-on-year increase of 4.47 times. The growth in profit is mainly due to a significant increase in revenue, reflecting the successful implementation of key strategies for developing major customer sales.

However, due to the slowdown in China's livestock industry, the demand for the company's veterinary pharmaceutical products has also decreased since the third quarter of 2025. The group's unaudited quarterly profit attributable to shareholders for the three months ending September 30, 2025, is expected to drop to approximately USD 6.5 million, compared to USD 9.3 million for the three months ending June 30, 2025